BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 30719075)

  • 1. Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma.
    Li N; Zhu Y
    Therap Adv Gastroenterol; 2019; 12():1756284818821560. PubMed ID: 30719075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins.
    Li J; Zhu Y
    Front Cell Dev Biol; 2020; 8():548335. PubMed ID: 33117795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research Progress on Regulating LncRNAs of Hepatocellular Carcinoma Stem Cells.
    Zhang X; Zhu Y
    Onco Targets Ther; 2021; 14():917-927. PubMed ID: 33603396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment.
    Song YJ; Zhang SS; Guo XL; Sun K; Han ZP; Li R; Zhao QD; Deng WJ; Xie XQ; Zhang JW; Wu MC; Wei LX
    Cancer Lett; 2013 Oct; 339(1):70-81. PubMed ID: 23879969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells.
    Li Y; Chen G; Han Z; Cheng H; Qiao L; Li Y
    Onco Targets Ther; 2020; 13():9721-9730. PubMed ID: 33061451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Regulatory Mechanisms Involved in Liver Cancer Stem Cell Properties in Hepatocellular Carcinoma.
    Lv D; Chen L; Du L; Zhou L; Tang H
    Front Cell Dev Biol; 2021; 9():691410. PubMed ID: 34368140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cancer stem cells as a therapeutic approach in liver cancer.
    Zhou G; Wilson G; George J; Qiao L
    Curr Gene Ther; 2015; 15(2):161-70. PubMed ID: 25537770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC.
    Qiu L; Li H; Fu S; Chen X; Lu L
    Oncol Lett; 2018 Feb; 15(2):2039-2048. PubMed ID: 29434903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis.
    Ma YS; Lv ZW; Yu F; Chang ZY; Cong XL; Zhong XM; Lu GX; Zhu J; Fu D
    J Exp Clin Cancer Res; 2018 Oct; 37(1):252. PubMed ID: 30326936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells.
    Huo X; Han S; Wu G; Latchoumanin O; Zhou G; Hebbard L; George J; Qiao L
    Mol Cancer; 2017 Oct; 16(1):165. PubMed ID: 29061150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel therapeutic strategies for treatment of hepatocellular carcinoma: targeting intervention on liver cancer stem cells].
    Li X; Luo Q; Song G
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Aug; 30(4):894-8. PubMed ID: 24059077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies.
    Wang N; Wang S; Li MY; Hu BG; Liu LP; Yang SL; Yang S; Gong Z; Lai PBS; Chen GG
    Ther Adv Med Oncol; 2018; 10():1758835918816287. PubMed ID: 30622654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.
    Zheng BN; Ding CH; Chen SJ; Zhu K; Shao J; Feng J; Xu WP; Cai LY; Zhu CP; Duan W; Ding J; Zhang X; Luo C; Xie WF
    Theranostics; 2019; 9(9):2606-2617. PubMed ID: 31131056
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Kwon M; Jung HJ
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluid shear stress induces cell migration via RhoA-YAP1-autophagy pathway in liver cancer stem cells.
    Yan Z; Guo D; Tao R; Yu X; Zhang J; He Y; Zhang J; Li J; Zhang S; Guo W
    Cell Adh Migr; 2022 Dec; 16(1):94-106. PubMed ID: 35880618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133
    Song Y; Park IS; Kim J; Seo HR
    Chem Biol Interact; 2019 Aug; 309():108713. PubMed ID: 31226288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long noncoding RNA in liver cancer stem cells.
    Cai Z; Xu K; Li Y; Lv Y; Bao J; Qiao L
    Discov Med; 2017 Sep; 24(131):87-93. PubMed ID: 28972877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.
    Wang R; Sun Q; Wang P; Liu M; Xiong S; Luo J; Huang H; Du Q; Geller DA; Cheng B
    Oncotarget; 2016 Feb; 7(5):5754-68. PubMed ID: 26735577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
    Shen YN; He HG; Shi Y; Cao J; Yuan JY; Wang ZC; Shi CF; Zhu N; Wei YP; Liu F; Huang JL; Yang GS; Lu JH
    Mol Carcinog; 2017 Feb; 56(2):751-760. PubMed ID: 27478926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway.
    Wang X; Wang R; Bai S; Xiong S; Li Y; Liu M; Zhao Z; Wang Y; Zhao Y; Chen W; Billiar TR; Cheng B
    J Exp Clin Cancer Res; 2019 Dec; 38(1):505. PubMed ID: 31888685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.